NMRA: Neumora Therapeutics Inc

FinancialsDividends

$1.62

-0.02

(-1.22%)

As of 08/22/2025 5:00 PM ET • Disclaimer
Powered by Stocksift.com

100%

NMRA Performance Snapshot

1-Week Chg

-0.61%

1-Month Chg

-14.29%

3-Month Chg

125.63%

6-Month Chg

-10.00%

1-Year Chg

-85.91%

Year-To-Date Chg

-17.77%

Beta 1-Year

2.90

Beta 5-Year

2.24

Volatility (10-Day)

3.97%

NMRA Technical Snapshot

Datesorted descending
Close
Change 1D
Open
High
Low
Typical
Volume

2025-08-22

$1.62

-$0.02 (-1.22%)

$1.66

$1.70

$1.61

$1.64

339.00K ($549.18K)

2025-08-21

$1.64

$0.03 (1.86%)

$1.59

$1.65

$1.57

$1.62

324.00K ($531.36K)

2025-08-20

$1.61

$0 (0%)

$1.60

$1.65

$1.56

$1.61

591.00K ($951.51K)

2025-08-19

$1.61

-$0.03 (-1.83%)

$1.63

$1.66

$1.56

$1.61

332.00K ($534.52K)

2025-08-18

$1.64

$0.01 (0.61%)

$1.66

$1.68

$1.60

$1.64

360.00K ($590.40K)

2025-08-15

$1.63

$0.05 (3.16%)

$1.58

$1.78

$1.57

$1.66

889.00K ($1.45M)

2025-08-14

$1.58

$0.02 (1.28%)

$1.56

$1.60

$1.49

$1.56

599.00K ($946.42K)

2025-08-13

$1.56

$0.06 (4%)

$1.50

$1.60

$1.50

$1.55

484.00K ($755.04K)

2025-08-12

$1.50

$0.06 (4.17%)

$1.42

$1.54

$1.39

$1.48

601.00K ($901.50K)

2025-08-11

$1.44

-$0.02 (-1.37%)

$1.49

$1.49

$1.41

$1.45

339.00K ($488.16K)

NMRA Financial Snapshot

Balance Sheet

(USD)

2025 Q2

Y/Y CHANGE

  • Cash and equivalents

    $124.52M

    -18.02%

  • Total assets

    $223.82M

    -44.66%

  • Total liabilities

    $40.95M

    76.38%

  • Total investments

    $93.06M

    -57.88%

  • Shareholders' equity

    $182.88M

    -52.03%

  • Book value per share

    $1.13

    -52.84%

Income Statement

(USD)

2025 Q2

Y/Y CHANGE

  • Revenue

    $0

    0%

  • Net income

    -$52.73M

    10.17%

  • Operating expense

    $54.04M

    -15.33%

  • Gross profit

    $0

    0%

  • EBITDA

    -$51.79M

    10.10%

  • Earnings per share

    -$0.33

    10.81%

Cash Flow

(USD)

2025 Q2

Y/Y CHANGE

  • Net change in cash

    -$3.55M

    88.99%

  • Cash from operations

    -$52.40M

    6.68%

  • Cash from investing

    $30.40M

    43.01%

  • Cash from financing

    $18.46M

    595.44%

  • Free cash flow

    -$52.32M

    6.83%

  • Free cash flow per share

    -$0.32

    8.22%

Metrics

(USD)

2025 Q2

Y/Y CHANGE

  • Market capitalization

    $118.61M

    -92.44%

  • Enterprise value

    -$8.53M

    -100.61%

  • Shares outstanding

    161.75M

    1.39%

  • Profit margin

    -

    -

  • Gross margin

    -

    -

  • EBITDA margin

    -

    -

Dividends

(USD)

2025 Q2

Y/Y CHANGE

  • Dividend yield

    0%

    0%

  • Dividends per share

    $0

    0%

  • Dividend growth

    -

    -

  • Payout ratio

    0%

    0%

  • Coverage ratio

    -

    -

  • Current ratio

    10.54

    -38.83%

View Financial Statements